Drug intelligence / Profile preview

DW1023

Development stage: Preclinical
Lead developer: Dongwha Pharmaceutical
Modality: Small Molecules

Overview

DW1023 is a small molecule oncology candidate currently under development by Dong Wha Pharm. It is specifically being investigated for the treatment of lymphoma. According to the company's research and development pipeline, the drug has successfully progressed through hit identification, lead optimization, and candidate selection phases, and is currently in the preclinical stage of development. As an innovative new drug, it represents part of Dong Wha's expansion into targeted cancer therapies.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on DW1023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW1023.

Explore the full profile